Berlin, 10 July 2019 – Medios AG (‘Medios’), one the leading Specialty Pharma companies in Germany, has held its 2019 Annual General Meeting today. All agenda items were passed with a large majority. Altogether, around 64 per cent of the share capital was present. The agenda items included, among others, the discharge of the Management Board and Supervisory Board members, the election of the auditor as well as the creation of a new authorized and a new contingent capital 2019. In addition, the shareholders approved a profit-and-loss transfer agreement with Medios Analytics GmbH. The voting results for the agenda items can be found on the Medios AG website at https://medios.ag/en/investor-relations/general-assembly.
In the course of the Annual General Meeting, the Management Board of Medios AG presented its growth strategy and confirmed its forecast for the 2019 financial year. Accordingly, it is still anticipating group sales of EUR 430 to 440 million, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, of EUR 16.5 to 17.5 million, and earnings before taxes (EBT), adjusted for extraordinary expenses*, of EUR 14.5 to 15.5 million. This represents sales growth of 31 to 34 per cent as well as a further increase in adjusted operating earnings*.
Matthias Gärtner, CFO of Medios AG: ‘We would like to sincerely thank our shareholders for the trust they have placed in us. We remain very confident that we will continue the Medios Group’s dynamic growth course in the current financial year and increase our profitability once again.’
* EBITDA and EBT are both adjusted for extraordinary expenses for stock options in the amount of EUR 1.1 million (non-cash). EBT is additionally adjusted for extraordinary expenses of EUR 0.6 million (non-cash) for amortization on the customer base following the acquisition of operating units of BerlinApotheke Schneider & Oleski oHG.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
Kirchhoff Consult AG
Tel.: +49 40 60918618
Fax: +49 40 60918660
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.